"Double-Blind Method" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
| Descriptor ID |
D004311
|
| MeSH Number(s) |
E05.318.780.300 E05.581.500.300 N05.715.360.780.320 N06.850.520.445.300
|
| Concept/Terms |
Double-Blind Method- Double-Blind Method
- Double Blind Method
- Double-Blind Methods
- Method, Double-Blind
- Methods, Double-Blind
- Double-Masked Method
- Double Masked Method
- Double-Masked Methods
- Method, Double-Masked
- Methods, Double-Masked
- Double-Masked Study
- Double Masked Study
- Double-Masked Studies
- Studies, Double-Masked
- Study, Double-Masked
- Double-Blind Study
- Double Blind Study
- Double-Blind Studies
- Studies, Double-Blind
- Study, Double-Blind
|
Below are MeSH descriptors whose meaning is more general than "Double-Blind Method".
Below are MeSH descriptors whose meaning is more specific than "Double-Blind Method".
This graph shows the total number of publications written about "Double-Blind Method" by people in this website by year, and whether "Double-Blind Method" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 3 | 3 |
| 1994 | 0 | 8 | 8 |
| 1995 | 0 | 3 | 3 |
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 8 | 8 |
| 1998 | 0 | 9 | 9 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 5 | 5 |
| 2002 | 0 | 9 | 9 |
| 2003 | 0 | 8 | 8 |
| 2004 | 0 | 10 | 10 |
| 2005 | 0 | 12 | 12 |
| 2006 | 0 | 7 | 7 |
| 2007 | 0 | 11 | 11 |
| 2008 | 0 | 12 | 12 |
| 2009 | 0 | 15 | 15 |
| 2010 | 0 | 14 | 14 |
| 2011 | 0 | 7 | 7 |
| 2012 | 0 | 12 | 12 |
| 2013 | 0 | 11 | 11 |
| 2014 | 0 | 9 | 9 |
| 2015 | 0 | 19 | 19 |
| 2016 | 0 | 15 | 15 |
| 2017 | 0 | 19 | 19 |
| 2018 | 0 | 19 | 19 |
| 2019 | 0 | 15 | 15 |
| 2020 | 0 | 21 | 21 |
| 2021 | 0 | 14 | 14 |
| 2022 | 0 | 5 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Double-Blind Method" by people in Profiles.
-
Bicephalic Transcranial Direct-Current Stimulation Does Not Add Benefits to a Footdrop Stimulator for Improving Functional Mobility in People With Chronic Hemiparesis After Stroke: A Double-Blind, Randomized Controlled Trial. Phys Ther. 2022 08 04; 102(8).
-
Fill levels, cost comparisons, and expulsion force requirements of commonly used topical ophthalmic steroids. J Cataract Refract Surg. 2022 Apr 01; 48(4):475-480.
-
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis. 2022 07; 81(7):951-961.
-
Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus. N Engl J Med. 2022 03 17; 386(11):1034-1045.
-
Neuronally-enriched exosomal microRNA-27b mediates acute effects of ibuprofen on reward-related brain activity in healthy adults: a randomized, placebo-controlled, double-blind trial. Sci Rep. 2022 01 17; 12(1):861.
-
Autologous Umbilical Cord Blood-Derived Mononuclear Cell Therapy Promotes Cardiac Proliferation and Adaptation in a Porcine Model of Right Ventricle Pressure Overload. Cell Transplant. 2022 Jan-Dec; 31:9636897221120434.
-
Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. Rheumatology (Oxford). 2021 11 03; 60(11):5379-5389.
-
Infant Metabolome in Relation to Prenatal DHA Supplementation and Maternal Single-Nucleotide Polymorphism rs174602: Secondary Analysis of a Randomized Controlled Trial in Mexico. J Nutr. 2021 11 02; 151(11):3339-3349.
-
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. Eur J Cancer. 2021 11; 157:415-423.
-
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. Gynecol Oncol. 2021 10; 163(1):41-49.